Kligman’s Formula: The Gold Standard for Managing Melasma

Personalised Medicine, Personalised Treatments, Skincare Solutions / By

Melasma is an acquired hyperpigmentary disorder characterized by symmetrical, light-to-dark brown macules and patches appearing predominantly across the face—specifically the cheeks, forehead, upper lip, and mandible. Due to its prominent facial distribution, it can carry a profound psychosocial impact, often affecting self-confidence and quality of life.

While it remains a challenging condition to manage, dermatologists have relied on a particular synergistic topical blend as a first-line treatment for over fifty years: Kligman’s Formula. First developed in 1975 by Dr Albert Kligman and Dr Willis, this topical “triple combination” cream remains the benchmark against which newer depigmenting therapies are evaluated.

What is Kligman’s Formula?

The original formula developed by Kligman and Willis was a targeted combination of three distinct active ingredients mixed into a hydrophilic cream base:

  1. A Skin-Lightening Agent (5%): Inhibits tyrosinase, the rate-limiting enzyme responsible for producing melanin (skin pigment).

  2. A Topical Vitamin A (0.1%): Increases epidermal cell turnover (epidermopoiesis), which accelerates the shedding of existing pigment, while simultaneously facilitating deeper penetration of the other active ingredients.

  3. A Mild Corticosteroid (0.1%): Functions primarily to suppress inflammation and irritation caused by the first two components, while exerting a mild, secondary depigmenting effect of its own.

Modern clinical dermatology frequently utilises Modified Kligman’s Formula (mKF). Because the high concentrations in the original standard often triggered intense skin irritation, modern modifications vary the strengths—such as reducing the lightening agent to 2–4% and the topical vitamin A to 0.025–0.05%—or substituting alternative, well-tolerated corticosteroids to match an individual’s skin type.

Commonly Asked Questions (FAQs)

How long does Kligman’s Formula take to work?

Initial improvements or a visible reduction in hyperpigmentation can often be observed within 4 weeks of daily compliance. However, achieving optimal stabilization and clearing of the pigmentary patches typically requires a continuous, monitored treatment course lasting 3 to 6 months.

Can I use Kligman’s Formula long-term?

No. Kligman’s formula is strictly intended for short-term, episodic use (typically capped at a maximum of 3 to 6 months). Prolonged, unmonitored use risks substantial structural changes to the dermal layers and localized complications. Once the pigment clears, your practitioner will transition you to a non-steroidal maintenance regimen.

Why is it not available standard over-the-counter?

Because of the potency of the prescription-strength retinoid and the inclusion of a topical corticosteroid, this treatment can only be legally and safely obtained via a doctor’s prescription. In Australia, these specific multi-ingredient combination creams are not listed on the Pharmaceutical Benefits Scheme (PBS) as pre-manufactured products, meaning they must be tailored individually.

The Crucial Role of Compounding Pharmacies

Because the exact commercial ratios available internationally (such as certain FDA-approved triple creams) are restricted or omitted from regular Australian manufacturing lines, custom compounding pharmacies bridge a critical clinical gap.

  • Tailored Strength Ratios: Every individual possesses a distinct Fitzpatrick skin type and varying thresholds for irritation. A compounding pharmacist can explicitly scale down the retinoid or skin-lightening agent percentages to minimize the risk of post-inflammatory hyperpigmentation.

  • Interchangeable Corticosteroids: Australian prescribing guidelines allow practitioners to swap out the classic dexamethasone for highly accessible, low-to-medium potency local alternatives—such as hydrocortisone 1% or triamcinolone acetonide 0.02%—depending on patient tolerance.

  • Elimination of Common Irritants: Mass-produced topical creams frequently contain specific preservatives, fragrances, or texturizing chemicals that can cause contact dermatitis or trigger vascular flushing. Compounding pharmacies can formulate the active ingredients in clean, hypoallergenic bases.

How to Correctly Apply the Compounded Product

To maximize structural pigment clearance while keeping irritation minimal, a strict application protocol must be maintained:

Step Action Timing / Volume Why It Matters
1. Prepare Night-time Application Only Apply strictly before bed The active retinoid is highly photosensitive and degrades rapidly under UV light. It also increases your skin’s vulnerability to solar damage.
2. Wash Cleanse & Dry Thoroughly Wait 15–20 minutes after washing Wash with an exceptionally gentle, soap-free cleanser. Applying potent active compounds to damp skin accelerates absorption too rapidly, significantly driving up the risk of severe peeling and redness.
3. Apply Apply a Pea-Sized Amount A single, minuscule pea-sized bead for the whole face Smooth it into a thin, nearly invisible film across the affected hyperpigmented regions. Avoid sensitive areas like the corners of the mouth, eyes, and nostrils to prevent deep irritation.
4. Hydrate Follow with a Basic Moisturiser Wait 10 minutes after application Allow the compounded cream to fully absorb into the skin matrix first, then follow up with a plain, non-comedogenic, barrier-repairing moisturiser to mitigate dryness and flaking.

 

Possible Side Effects

While highly effective, Kligman’s formula contains reactive therapeutic agents that alter skin behavior. Side effects can be classified into expected, transient adjustments and adverse events resulting from prolonged use:

Common & Transient Side Effects Long-Term / Adverse Risks (Prolonged Use)
Erythema: Mild to moderate skin redness. Steroid-Induced Atrophy: Thinning of the skin architecture.
Desquamation: Superficial skin peeling or flaking. Telangiectasia: Prominent, permanently dilated surface blood vessels.
Mild Pruritus: Transient itching or tingling upon application. Exogenous Ochronosis: A rare, blue-black deep dermal soot-like pigmentation.
Photosensitivity: Increased susceptibility to sunburns. Acneiform Eruptions: Steroid-induced localized breakouts.

Clinical Warning: If you experience severe burning, swelling, or raw weeping of the skin, cease application immediately and contact your prescribing physician or dermatologist.

Highly Targeted Lifestyle Tips for Managing Melasma

Melasma melanocytes are pathologically hyper-reactive. While general advice often stops at “wear sunscreen,” long-term management requires mitigating specific triggers that upregulate pigment pathways:

  • Block Invisible High-Energy Visible (HEV) Blue Light: Traditional chemical sunscreens block UV rays but fail to stop blue light from screens and overhead lighting, which significantly drives pigment production in darker skin types. Ensure your daily sun protection contains Iron Oxides, a mineral ingredient clinically proven to form a physical shield against visible blue light.

  • Avoid Ambient Thermal Heat: Melanocytes are stimulated by heat just as much as UV light. Avoid prolonged exposure to saunas, hot yoga classes, steam rooms, or standing directly over hot stoves and ovens. If you become overheated, gently press a cold towel to your face to bring down skin temperature instantly.

  • Review Mechanical Friction: Chronic physical rubbing can trigger post-inflammatory pigment signals. Eliminate harsh facial scrubs, abrasive cleansing brushes, and vigorous towel-drying. Swap to silk pillowcases to minimize nocturnal facial friction.

  • Incorporate Targeted Tyrosinase Inhibitors into Maintenance: During your “off-cycles” from Kligman’s formula, look into cosmetic serums containing Kojic Acid, Arbutin, or Ascorbic Acid (Vitamin C). These slow down melanin synthesis through alternative biochemical pathways without the side-effect profile of standard prescription compounds.

Ready to Learn More or Get Support?

References

  • Majid, I. (2010). Mometasone-based triple combination therapy in melasma: Is it really safe? Indian Journal of Dermatology, 55(4), 359–362. https://doi.org/10.4103/0019-5154.74545 Cited by: 52

  • Aldhafiri, M., Almutairi, M., Alutaibi, H. M., Aldandan, H. R., Albshr, F. A., & Alkhalifa, F. S. (2021). Attitude toward using the triple combination bleaching formula and related outcomes: A cross-sectional study. Cureus, 13(12), e20542. https://doi.org/10.7759/cureus.20542 Cited by: 6

  • Doolan, B. J., & Gupta, M. (2021). Melasma. Australian Journal of General Practice, 50(12), 880–885. https://doi.org/10.31128/ajgp-05-21-6002

  • Sachdev, M., Grimes, P. E., Callender, V., Hartman, C. L., Taylor, S. C., Elbuluk, N., Badawi, A., Funasaka, Y., Lim, J., Ngee, C. Y., & Desai, S. R. (2024). Cysteamine isobionic-amide complex versus Kligman’s formula for the treatment of melasma: Equal efficacy and rapid onset of action. Journal of Drugs in Dermatology, 23(2), 9–16. https://doi.org/10.36849/jdd.7428 Cited by: 9

  • Wu, B. Q., Wang, Y. J., Chang, C. C., Juang, T. Y., Huang, Y. H., & Hsu, Y. C. (2024). Clinical efficacy of cysteamine application for melasma: A meta-analysis. Journal of Clinical Medicine, 13(23), 7483. https://doi.org/10.3390/jcm13237483 Cited by: 5

  • Aung, T., Elghblawi, E., & Aung, S. T. (2024). Melasma management in primary care. Australian Journal of General Practice, 53(Suppl 12), S56–S60. https://doi.org/10.31128/ajgp-03-24-7189

You might also like...

Shopping Cart